I want to thank all for creating the foundation and website. 9 years ago when I was diagnosed there was little information available. I had to do a lot of research on my own. The work you are doing is awesome! No one should ever die from anal cancer.

Maria

Since the Foundation’s inception in 2010 we have dedicated ourselves to improving the lives of anal cancer thrivers, supporting and funding research for anal cancer as well as HPV-related cancers, creating a collaborative space for clinicians to share knowledge and ideas, and moving the pendulum forward in increasing vaccination rates for girls and boys. We continue to work with leaders in the field to not only eradicate HPV-related cancers for future generations, but to eliminate research and scientific silos and bring improved and novel treatments to those diagnosed with anal cancer.

Our staff and boards work every day to improve the once bleak landscape facing the anal cancer community. It is our promise and commitment that tomorrow will  be different for our community!

The difference your 2017 contribution made

A New Age in Anal Cancer Treatment

A New Age in Anal Cancer Treatment

Scientific progress

The promise of a cure got closer this year through the first advance in anal cancer treatment in 42 years. Working with a powerhouse research team at MD Anderson Cancer Center, we funded the first phase II immunotherapy trial ever conducted in anal cancer patients. The study achieved an unprecedented 24% response rate to the new immunotherapy, Nivolumab. Further, it was well tolerated with minimal side effects.

Fighting for Equitable Cancer Prevention

Fighting for Equitable Cancer Prevention

Cancer prevention for all

Another 3 countries expanded their female-only program to boys, bringing the total of countries vaccinating both genders to 15. In the UK, we rallied oncologists, medical experts and coalition members to change the JCVI's decision to not vaccinate boys. BBC covered the story, interviewing co-Founder Tristan Almada in a 12 minute live segment where he highlighted the clear flaws in the UK government's thinking. In November, we were pleased to see the committee acknowledged that their decision was based on outdated information. We expect the decision to be reversed in 2018 and UK boys to be finally be protected as well.

Racing To End Preventable Cancer

Racing To End Preventable Cancer

Advocacy in motion

Our NOMAN is an Island: Race To End HPV teams sped across the Mediterranean this summer with a record 8 crews rowing 200 miles each! The NOMAN campaign challenges individuals to extreme endurance events, raising awareness of the connection between HPV and cancer. This year, we raised over $600,000 and featured NOMAN's first all-female team. Watch highlights at www.nomancampaign.org.

A Cure for 5% of the World's Cancer

A Cure for 5% of the World's Cancer

Scientific collaboration

The Foundation supports novel and groundbreaking research into finding new treatments that benefits all HPV-related cancers. We are excited to have helped fund and develop the first ever trial to seek a therapy targeted to multiple HPV-related cancers simultaneously. The trial is currently accruing patients across the country at Dana-Farber Cancer Institute.

Foundation Honored

Foundation Honored

Recognized for contributions

In Boston, Co-Founder Justine Almada was honored as Mass General's annual One Hundred gala, an evening celebrating game-changers in the cancer community. The award stated that the Foundation has "an ambitious vision: develop new cures for and eliminate this cancer and its cause."

Supporting You

Supporting You

Peer-to-Peer Support

Our Peer to Peer Support Program continues to alleviate the isolation that many thrivers and caregivers encounter after diagnosis. We hear from thrivers that the information received from their peer mentors is often more helpful than what their medical team provides. Thank you to all the peer volunteers who have given their time and energy to this program.